MeVis Medical Solutions AG
MeVis Medical Solutions AG Fundamental Analysis
MeVis Medical Solutions AG (M3V.DE) shows moderate financial fundamentals with a PE ratio of 17.26, profit margin of 28.48%, and ROE of 13.44%. The company generates $0.0B in annual revenue with weak year-over-year growth of -2.13%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 54.2/100 based on profitability, valuation, growth, and balance sheet metrics. The C grade reflects average fundamentals, with notable risks in certain areas.
Fundamental Health Score
We analyze M3V.DE's fundamental strength across five key dimensions:
Efficiency Score
WeakM3V.DE struggles to generate sufficient returns from assets.
Valuation Score
ExcellentM3V.DE trades at attractive valuation levels.
Growth Score
WeakM3V.DE faces weak or negative growth trends.
Financial Health Score
ExcellentM3V.DE maintains a strong and stable balance sheet.
Profitability Score
WeakM3V.DE struggles to sustain strong margins.
Key Financial Metrics
Is M3V.DE Expensive or Cheap?
P/E Ratio
M3V.DE trades at 17.26 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, M3V.DE's PEG of -0.68 indicates potential undervaluation.
Price to Book
The market values MeVis Medical Solutions AG at 2.33 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 27.34 times EBITDA. This signals the market has high growth expectations.
How Well Does M3V.DE Make Money?
Net Profit Margin
For every $100 in sales, MeVis Medical Solutions AG keeps $28.48 as profit after all expenses.
Operating Margin
Core operations generate 31.71 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.44 in profit for every $100 of shareholder equity.
ROA
MeVis Medical Solutions AG generates $9.28 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
MeVis Medical Solutions AG generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.
Free Cash Flow
MeVis Medical Solutions AG generates weak or negative free cash flow of $0.00, restricting financial flexibility.
FCF Per Share
Each share generates $0.00 in free cash annually.
FCF Yield
M3V.DE converts 0.00% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
17.26
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.68
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.33
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.92
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.58
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.09
vs 25 benchmark
ROCE
Return on capital employed
0.13
vs 25 benchmark
How M3V.DE Stacks Against Its Sector Peers
| Metric | M3V.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 17.26 | 28.81 | Better (Cheaper) |
| ROE | 13.44% | 643.00% | Weak |
| Net Margin | 28.48% | -44312.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.36 | Strong (Low Leverage) |
| Current Ratio | 1.58 | 4.50 | Neutral |
| ROA | 9.28% | -17799.00% (disorted) | Weak |
M3V.DE outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews MeVis Medical Solutions AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-6.09%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
-43.49%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-51.93%
Industry Style: Defensive, Growth, Innovation
Declining